MXCT logo

MAXCYTE INC

MXCTNASDAQ
🏆 #3747 by market capUS Equity
$1.71▲ $0.01 (+0.88%)
After hours · at close
🔔
Track MXCT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.9%
7d▲ 19.2%
14d▲ 31.5%
30d▲ 43.7%
ytd▲ 10.7%
1y▲ 12.5%
🏦Market Cap
$176M
Small Cap
📈Revenue Growth (YoY)
-14.5%
Declining
📊Gross Margin
79.4%
High
💵FCF Margin
-76.6%
Thin
⚖️P/S Ratio
5.1x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.66 – $1.76
52-Week Range
$0.64 – $1.81
Volume (shares)
102,174
Avg Volume (shares)
—
Shares Outstanding
103.2M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$33M
Last Q Revenue
$7M
P/E Ratio
-4.6
P/S Ratio
5.1x
EPS (TTM)
$-0.33
Dividend Yield
0.00%
Dilution (1yr)
+1.5%
MXCT logo

MAXCYTE INC

MXCT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$33M▼ −14.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
81.2%▼ −0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$45M▼ −11.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$36M▲ +23.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
106.4M▲ +1.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$8M YoY
StockOtter · stockotter.space

About MAXCYTE INC

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.